Aviado · Research
Longevity Daily
Wednesday, July 29, 2026
Listen
Today's Brief
Today's headline is a striking reality check for GLP-1 enthusiasts: Ozempic failed to slow Alzheimer's disease progression in the rigorous EVOKE Phase 3 trial, despite observational data pointing to a 40–70% risk reduction — a gap that underscores just how unreliable real-world data can be. On the encouraging side, a 16,000-person, 3-year RCT confirms daily multivitamins genuinely support functional health in older adults, and new research rewrites how metformin actually works. The FDA's peptide advisory panel also made a significant regulatory move this week, while a 15-RCT systematic review confirms exercise remains the only intervention with consistent healthspan evidence.
10 stories5 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Ozempic Fails Its Alzheimer's Test: The EVOKE Phase 3 Trial Should Change How You Think About GLP-1 Hype
Semaglutide (Ozempic/Wegovy) failed to meaningfully slow Alzheimer's disease progression in the landmark EVOKE Phase 3 trial — one of the most rigorous looks at GLP-1-based neuroprotection ever conducted, using MRI, CSF biomarkers, and cognitive composites as endpoints. What makes this result particularly striking is the chasm between this and prior evidence: a target-trial emulation of over 1 million diabetic patients had shown a 40–70% lower risk of first-time AD diagnosis with semaglutide versus other antidiabetic drugs. The EVOKE failure doesn't definitively close the door on GLP-1s in brain aging, but it is a sobering reminder that observational data and RCT outcomes can diverge sharply — and that narrative-driven hype around a drug class is not the same as proven efficacy. If you've been banking on Ozempic as a cognitive longevity strategy, this trial demands a serious reassessment.
Read more →Consistent Daily Routines Cut Pain and Depression in Older Adults — Even When Sleep Is Poor
Older adults who maintained consistent schedules for waking, eating, and going to sleep showed significantly reduced physical pain and depressive symptoms — and the protective effect was strong enough to buffer the health damage typically caused by insomnia. The findings highlight circadian rhythm synchronization as a free, immediately actionable intervention that may rival more expensive approaches to cognitive and physical resilience. For longevity optimizers, this reframes "sleep hygiene" from a vague suggestion into a precise timing discipline with measurable outcomes.
Read more →Supplements & Compounds
Daily Multivitamin Supports Functional Health in 16,000 Older Adults Over Three Years
Researchers at Augusta University found that adults aged 60 and older who took a daily multivitamin showed significantly better functional health outcomes after three years compared to a placebo group, in one of the largest and longest supplement trials of its kind. Presented at the 2026 American Society for Nutrition conference, the improvements covered real-world markers — walking endurance, carrying capacity, and daily energy — not just blood biomarkers. At this sample size and duration, this is one of the harder-to-dismiss supplement findings we've seen for healthy aging.
Read more →Lifelong PQQ Supplementation Reduced Midlife Mortality Risk and Slowed Muscle Decline in Aging Mice
Lifelong supplementation with PQQ (pyrroloquinoline quinone) and its derivative IPQ significantly reduced mortality risk during midlife and delayed age-related muscle function decline in senescence-accelerated mice. This is a mouse study, so direct clinical extrapolation requires caution. But PQQ's established role in supporting mitochondrial biogenesis and antioxidant defense makes the mechanism biologically credible, and this study adds meaningful momentum to an emerging body of animal evidence ahead of human trials.
Read more →Research & Papers
Metformin's Mechanism Gets Rewritten: It Works Through the Gut, Not the Liver
New research overturns the long-held assumption that metformin primarily works by suppressing glucose production in the liver — the drug's core mechanism appears to operate through the gut lining instead. The finding matters well beyond diabetes: metformin is under active study as a longevity and cancer-prevention drug, and clinical investigators have struggled to predict who will benefit because the mechanism was poorly understood. A clearer gut-based mechanism could reshape how future aging trials are designed and how dosing protocols are calibrated.
Read more →Aviado Research: This Week's Featured Deep-Dive
In this edition's Aviado Research analysis, our team examines the current evidence base for a key area of longevity science. As always, we go beyond the headlines to assess what the research actually supports, flag gaps in the evidence, and distill actionable takeaways for the health-conscious reader. Read the full analysis for our complete evidence breakdown.
Read the full Aviado analysis →Lifestyle & Nutrition
Exercise Is Still the Only Proven Healthspan Lever — 15 RCTs and 4,600 People Confirm It
A systematic review of 15 randomized controlled trials covering 4,656 predominantly older adults found that exercise — whether done alone or bundled into a multi-component program — is the single intervention with consistent evidence for improving multidimensional healthspan. No supplement, drug, or dietary intervention matched exercise in either the quality or consistency of the RCT evidence reviewed. If you're weighing where to put your time and money in longevity optimization, this review makes the answer hard to argue with.
Read more →Bryan Johnson's Sleep Protocol: Resting Heart Rate Before Bed Is His Most Important Biomarker
Longevity entrepreneur Bryan Johnson says his resting heart rate before bed is the most critical biomarker he tracks, and shares three specific sleep protocols aimed at lowering it as part of his goal to live well past 100. While Johnson's data-dense self-experimentation continues to attract scrutiny — and his personal n=1 approach is not a substitute for clinical evidence — his framework has meaningfully influenced how a generation of health optimizers approach sleep quality metrics. Take these tips as field-tested personal practice rather than proven longevity protocol.
Read more →Industry & Policy
FDA Advisers Dismiss Safety Warnings and Back Four Peptide Treatments for Return to Market
An FDA outside advisory panel has pushed back against regulator safety concerns and recommended approval for four previously banned peptide compounds — a move that could accelerate the return of widely used peptide treatments to the longevity and sports medicine markets. The peptide space has been operating in legal and regulatory flux, with clinics and biohackers using compounds that carry limited formal clinical evidence. This advisory ruling doesn't guarantee FDA approval, but it signals a significant shift in the regulatory winds worth watching closely.
Read more →Montana's Right-to-Try Law Enters a New Phase, Adding Longevity Experts to Its Review Board
Montana's first experimental treatment review board has brought in three longevity-focused advisors as the state's right-to-try law moves from policy into practice, potentially opening access to experimental therapies that haven't cleared standard FDA approval pathways. The development raises substantive questions about how much regulatory oversight is appropriate when patients demand access to interventions at the frontier of aging science. Whether this becomes a model for other states — or a cautionary tale — it's worth tracking as a real-world test of decentralized longevity regulation.
Read more →